Teva and mAbxience Expand Strategic Partnership to include an additional Oncology Biosimilar Candida
- The expansion of the strategic partnership reinforces the solid foundation of the collaborative efforts that commenced in April 2024
- The collaboration supports Teva's Pivot to Growth strategy and adds to the company’s biosimilar portfolio
- Both companies reaffirm their shared commitment to making high-quality, affordable treatments accessible to patients worldwide
TEL AVIV, ISRAEL and MADRID, Oct. 03, 2024 (GLOBE NEWSWIRE) - Teva Pharmaceuticals International GmbH, a subsidiary of Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) and mAbxience, a Fresenius Kabi majority-owned group with partial ownership from Insud Pharma, today announced a new global licensing agreement for the development of an anti PD-1 oncology biosimilar candidate. This marks the second agreement between the two companies, reinforcing the solid foundation of the collaborative efforts that commenced in April 2024.
The global agreement to develop an additional oncology biosimilar further strengthens the alliance between Teva and mAbxience, underscoring the shared goal to provide cost-effective, high-quality biosimilar treatments that address critical unmet needs in oncology care. By leveraging each company’s unique expertise and resources, the collaboration continues to drive innovation and accessibility in healthcare to create solutions for patients worldwide.
The licensing agreement includes exclusive rights for multiple markets, including Europe and the United States, and aligns with mAbxience's strategy for global expansion. The collaboration reflects Teva's progress advancing its Pivot to Growth strategy by adding a new biosimilar to the company’s broad portfolio of biosimilars, through focused partnerships and business development efforts.
Similar to the initial contract, under the terms of this agreement, mAbxience will lead the development and production of the biosimilar, utilizing its state-of-the-art, cGMP-compliant facilities in Spain and Argentina. Teva will manage regulatory approvals and oversee commercialization in the designated markets, ensuring that patients around the world gain access to this oncology treatment.
Angus Grant, PhD, Executive Vice President of Business Development at Teva, said, “We are excited to deepen our collaboration with mAbxience. This agreement not only strengthens our alliance but also highlights our shared dedication to expanding access to critical oncology treatments. This collaboration with mAbxience reflects Teva’s ideal strategic partnership model to optimize development costs, apply our regulatory expertise and leverage our extensive commercial capabilities to bring new treatment options to people living with serious medical conditions.”
“Building on our first agreement with Teva signed earlier this year, this second collaboration is a testament to the strength of our partnership and the shared vision of both companies,” added Jurgen Van Broeck, CEO of mAbxience. “This agreement reinforces our commitment to making high-quality biosimilars accessible and improving healthcare outcomes on a global scale.”
About Teva
Teva (NYSE and TASE: TEVA) is a global pharmaceutical leader with a category-defying portfolio, harnessing our generics expertise and stepping up innovation to continue the momentum behind the discovery, delivery, and expanded development of modern medicine. For over 120 years, Teva's commitment to bettering health has never wavered. Today, the company’s global network of capabilities enables its ~37,000 employees across 58 markets to push the boundaries of scientific innovation and deliver quality medicines to help improve health outcomes of millions of patients every day. To learn more about how Teva is all in for better health, visit www.tevapharm.com.
About mAbxience
mAbxience is a Spanish-based company specializing in the development, production, and commercialization of biopharmaceuticals. In August 2022, Fresenius Kabi and Insud Pharma entered into an agreement whereby Fresenius Kabi, an operating company of Fresenius, acquired a majority stake of mAbxience, making it a global, vertically integrated biotechnology company. With over a decade of expertise, our mission is clear: to provide accessible, affordable medicines across the globe, aiming to enhance the quality of life by ensuring universal access to high-caliber medicines. With two market-approved products and a robust pipeline in development, we have established a B2B presence in over 100 markets. Alongside this, we have formed a network with more than 30 partners and built a dedicated team of over 1,000 professionals. Our three multi-product facilities, located in Europe and South America, have obtained GMP approval from esteemed regulatory bodies, including the FDA, EMA, and others. Furthermore, as a global biopharmaceutical expert, mAbxience specializes in Contract Development and Manufacturing Organization services (CDMO), utilizing advanced technology and innovative platforms to deliver integrated manufacturing solutions. For more insights into mAbxience, our biosimilars and CDMO business, please visit our website (www.mabxience.com) or connect with us on LinkedIn.
Teva Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, which are based on management’s current beliefs and expectations and are subject to substantial risks and uncertainties, both known and unknown, that could cause our future results, performance or achievements to differ significantly from that expressed or implied by such forward-looking statements. You can identify these forward-looking statements by the use of words such as “should,” “expect,” “anticipate,” “estimate,” “target,” “may,” “project,” “guidance,” “intend,” “plan,” “believe” and other words and terms of similar meaning and expression in connection with any discussion of future operating or financial performance. Important factors that could cause or contribute to such differences include risks relating to: our ability to effectively execute and expand our collaboration with mAbxience for the development of oncology biosimilar candidates; our ability to lead the regulatory processes and commercialization of such biosimilar candidates in the designated markets; risks that regulatory approvals and other requirements may delay the development and commercialization of the biosimilar candidates; our ability to successfully launch and execute our Pivot to Growth strategy, including to expand our innovative and biosimilar medicines pipeline and profitably commercialize the innovative medicines and biosimilar portfolio, whether organically or through business development; and other factors discussed in this press release, in our Quarterly Report for the second quarter of 2024, and in our Annual Report on Form 10-K for the year ended December 31, 2023, including in the sections captioned “Risk Factors.” Forward-looking statements speak only as of the date on which they are made, and we assume no obligation to update or revise any forward-looking statements or other information contained herein, whether as a result of new information, future events or otherwise. You are cautioned not to put undue reliance on these forward-looking statements.
mAbxience contacts:
Media
Miguel Martínez-Cava, Global External Communication Manager: miguel.martinezcava@mabxience.com
Teva contacts
Media Contacts
Kelley Dougherty +1 (973) 832-2810
Eden Klein +972 (3) 906-2645
IR Contacts
Ran Meir +1 (267) 468-4475
Yael Ashman +972 (3) 914-8262
Sanjeev Sharma +1 (973) 658 2700
- “火来顺”致敬5·10中国品牌日签约中国人保责任险承保,为消费者保驾护航!
- 亿果联-即时零售
- 诺为泰凭借其临床研究监查员监查模拟计划荣膺布兰登·霍尔专业能力和技能发展金奖殊荣
- 央视《经济半小时》聚焦 长虹美菱智造向新
- 2023广东高价值商标品牌发展论坛暨成果发布会顺利举办
- 领跑数字化转型:望繁信科技荣登「2024智能自动化技术商Top 15」榜单
- 爱达邮轮部署华南,爱达·地中海号广州南沙启航在即
- 京东汽车与岚图战略签约 打造线上线下汽车消费新模式
- 张永志专栏 | 在行业大整合的新周期,顾家家居强势营销映射行业三大变局
- IBM watsonx为全球温网球迷带来全新的生成式AI数字体验
- WS数字迷踪:科技魔法师疑虑,WhatsApp营销工具是否是未知领域的钥匙
- 平安养老险山西分公司开展2024年“7.8全国保险公众宣传日”活动
- "旅游业必须引领更公平、更可持续的未来"——联合国旅游秘书长呼吁采取气候行动并为社区赋能
- ins/ig营销推广怎么做到自动吸客?instagram精准群发私信助手
- Bedford Metals Engages Grander Exploration for Ubiquity Lake Uranium Project Exploration Program
- Khara Inc.通过将存档数据迁移到Wasabi Hot Cloud Storage节省80%的运营和管理成本
- 德艺双馨演员凯丽亮相M榜荣誉之夜 彰显口碑影响力传递文艺正能量
- Urgent Call for Federal Investigation Into Town of Palm Beach Police: McWhorter Foundation Request
- 电磁灶微波炉电饭锅能效试验系统,二十年质保
- 长期房颤可致猝死和中风,步长青花瓷稳心,有效控制和预防房颤发作!
- 【再提新车】热烈祝贺上海腾发购买的徐工G2起重机批量发车
- Sony大屏幕电视机采用由KANEKA可生物降解聚合物Green PlanetTM制成的泡沫模塑产品作为缓冲材料
- 三元乙丙密封胶条十大品牌一线排行 -- 梵象胶条
- 春节之后“开门红”概率几何?
- 陕西平利:2024天书峡景区“五一”开园音乐盛典成功举办
- 全球先端实验室护肤品牌德妃DERMAFIRM连续6年荣获“韩国第一品牌大奖”
- 创新、引领、发展——SAMPE中国2024年会在京盛大开幕
- 138位国际精英肿瘤专家,助力美中爱瑞中外专家联合诊疗中心正式启航
- 《特簇之画》开机仪式:点燃希望之光
- 河北省慈善总会2024“祛白天使”白癜风公益援助正式启动!
推荐
- 产业数字化 为何需要一朵实体云? 改革开放前,国内供应链主要依靠指标拉动,其逻 资讯
- 新增供热能力3200万平方米 新疆最大热电联产项目开工 昨天(26日),新疆最大的热电联产项目—&md 资讯
- 中央气象台连发四则气象灾害预警 暴雪橙色预警+冰冻橙色预警+大雾黄色预警+ 资讯
- 国足13次出战亚洲杯首次小组赛0进球 北京时间1月23日消息,2023亚洲杯小组 资讯
- 周星驰新片《少林女足》在台湾省举办海选,吸引了不少素人和足球爱好者前来参加 周星驰新片《少林女足》在台湾省举办海选,吸 资讯
- 私域反哺公域一周带火一家店! 三四线城市奶茶品牌茶尖尖两年时间做到GMV 资讯
- 一个“江浙沪人家的孩子已经不卷学习了”的新闻引发议论纷纷 星标★ 来源:桌子的生活观(ID:zzdshg) 没 资讯
- 抖音直播“新红人”进攻本地生活领域 不难看出,抖音本地生活正借由直播向本地生活 资讯
- 大家一起关注新疆乌什7.1级地震救援见闻 看到热气腾腾的抓饭马上就要出锅、村里大家 资讯
- 男子“机闹”后航班取消,同机旅客准备集体起诉 1月4日,一男子大闹飞机致航班取消的新闻登上 资讯